Company profile for NEC OncoImmunity

NEC OncoImmunity

Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Contact Supplier

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

pharmacompass-1-m-2025-12-22

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

Contact Supplier

pharmacompass-2-m-2025-11-03

Contact Supplier

VISIT THE VIRTUAL BOOTH
Review portfolio & marketing content
CONTACT DETAILS
Google Map, LinkedIn, Emails...

DIGITAL CONTENT

2 News #PharmaBuzz

media
2 News #PharmaBuzz

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

OncoImmunity AS is a Norwegian company established to develop bioinformatics software that has the ability to empower precision cancer immunotherapy, and thus improve the outlook for patients with late-stage disease. We develop machine-learning methods, accessible online, applied to genomics data for tumor immune profiling. The company has just successfully completed a funding round and has attracted significant investment fro...

OncoImmunity AS is a Norwegian company established to develop bioinformatics software that has the ability to empower precision cancer immunotherapy, and thus improve the outlook for patients with late-stage disease. We develop machine-learning methods, accessible online, applied to genomics data for tumor immune profiling. The company has just successfully completed a funding round and has attracted significant investment from both life science and software investors. The company’s first software product offering will select optimal patients to be assigned to cancer immunotherapy clinical trials.

Tides AsiaTides Asia

Not Confirmed

Not Confirmed

24-26 February, 2026

Tokyo, Japan
BIO Partnering at JPMBIO Partnering at JPM

Not Confirmed

Not Confirmed

12-15 January, 2026

San Francisco Marriott Marquis, California
Biotech ShowcaseBiotech Showcase

Not Confirmed

Not Confirmed

12-14 January, 2026

San Diego, California, U.S.A

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown

Country

Country

Norway

Address

Address

Oslo Cancer Cluster, Innovation Park, Ullernchausséen 64, 0379, Oslo, Norway

Telephone

Telephone

4790015242

Email

enquiries@pharmacompass.com

Client Website

Website

https://www.oncoimmunity.com/

Linkedin

https://www.linkedin.com/company/oncoimmunity/

youtube

YouTube

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

NEC OncoImmunity publishes research using its neoantigen prediction technology

17 Oct 2023

// BUSINESSWIRE

NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets

07 Mar 2022

// GLOBENEWSWIRE

Drugs in Development

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Market Place

Home

Menu

Post Enquiry

Market Place

Search